相关实验视频
Updated: May 18, 2026

09:04
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
针对VEGF-B作为胰岛素抵抗和2型糖尿病的新疗法
Carolina E Hagberg1, Annika Mehlem, Annelie Falkevall
1Tissue Biology Group, Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Nature
|October 2, 2012
概括
抑制血管内皮生长因子B (VEGF-B) 信号传递可以改善2型糖尿病模型中的胰岛素敏感性和葡萄糖耐受性. 向VEGF-B可能为管理2型糖尿病提供新的治疗策略.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 血管生物学 血管生物学
背景情况:
- 全球2型糖尿病的患病率正在上升,多余的脂质沉积会影响胰岛素敏感性.
- 目前对子宫外脂质积累的治疗方法有限.
- 血管内皮生长因子B (VEGF-B) 调节肌肉中的脂肪酸运输.
研究的目的:
- 研究VEGF-B信号在2型糖尿病中的作用.
- 评估VEGF-B对抗性作为一种潜在的治疗策略.
主要方法:
- 在糖尿病db/db小鼠中遗传删除Vegfb.
- 在db/db小鼠和高脂肪饮食养的老鼠中使用抗体抑制VEGF-B信号的药理抑制.
主要成果:
- 在动物模型中,减少VEGF-B信号恢复了胰岛素敏感性和改善了葡萄糖耐受性.
- 遗传删除Vegfb可以防止异胎脂沉积,并维持正常血糖.
- 抑制VEGF-B保留了胰腺小岛结构,改善了β细胞功能,改善了脂质失调症.
结论:
- 阻断VEGF-B的信号传递增强了内皮细胞对脂质吸收的屏障功能.
- VEGF-B对抗是一种有前途的新型治疗方法,用于2型糖尿病.
- 向内皮脂运输可以改善胰岛素敏感性和葡萄糖的处置.
相关概念视频
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
